Baxter Shares Plummet as Device Crisis Deepens

The medical technology firm Baxter International finds itself navigating a severe corporate storm, with challenges extending far beyond disappointing quarterly earnings. At the heart of the turmoil lies the Novum IQ Large Volume Pump, an infusion device allegedly linked to patient safety risks. As attorneys assemble class-action lawsuits, investors are questioning the company’s ability to survive this escalating nightmare.

Financial Fallout Reflects Operational Crisis

When Baxter reported its quarterly results in late October, the financial impact of its operational troubles became starkly clear. Although the company posted improved adjusted earnings, it fell short of revenue expectations and was compelled to downgrade its full-year forecast. The market reaction was brutal: shares collapsed by more than 14 percent, hitting a low not seen in two decades.

Chief Financial Officer Joel Grade acknowledged the ongoing pressure, stating the entire infusion pumps division will remain under strain for as long as the shipping halt for the Novum LVP continues. The disruption is so significant that Baxter has slashed its 2025 operational revenue growth projection to a mere 1 to 2 percent.

A Leadership Change Amidst Mounting Pressure

Compounding the situation, Andrew Hider assumed the role of Chief Executive Officer just as the crisis intensified. While his public statements emphasize commitments to continuous improvement and sustainable growth, the Novum LVP predicament dominates the corporate agenda. The legal landscape looks increasingly threatening, with pending class actions that have a filing deadline of December 15, 2025, potentially amplifying the company’s liability.

Should investors sell immediately? Or is it worth buying Baxter?

Systemic Device Failures Trigger Safety Concerns

The core issue is profoundly serious. The Novum LVP is suspected of containing systemic flaws that have reportedly led to life-threatening scenarios, including under-dosing, over-dosing, and a complete cessation of fluid delivery. The consequences have been devastating, with the device being connected to numerous serious patient injuries and at least two fatalities.

The initial alarm sounded in April 2025 when a hospital network pulled all Novum pumps from service. Baxter responded by issuing warning letters to customers, and by July, the company enacted a “voluntary and temporary” suspension of all deliveries and installations. To date, no timeline has been established for resuming these activities.

Market analysts have largely maintained “Hold” ratings on the stock, though many have revised their price targets downward. Baxter continues to pursue other strategic priorities, including the launch of new products like the Welch Allyn Connex 360 Vital Signs Monitor. Nevertheless, the unresolved status of the Novum LVP shipping suspension continues to cast a long shadow over the company’s equity.

For shareholders, the critical uncertainty remains: Is this downturn a temporary setback, or is it the precursor to a more permanent decline?